

CORONAVIRUS DISEASE 2019 (COVID-19)

COVID-19 Pharmacy Benefit Plan Provisions



Audience: Clinically Integrated Network and Retail Pharmacy

Revision Date: 11/25/2020

Version: #2

COVID-19 Response Team Owner: Planning

Date of Last Review: 11/25/2020

What's changed – Deleted expired special programs; date update highlighted in yellow.

Pharmacy Benefit Plan Provisions During COVID-19

We are committed to proactively working together to respond to the global spread of COVID-19 and ensuring that we take care of our patients, communities and each other. Trinity Health and OptumRx have been working closely to respond the changing needs of our colleagues. Below is a summary of temporary actions to ensure members have access to medications.

Colleague prescriptions for hydroxychloroquine and chloroquine

Currently, our Trinity Health retail pharmacies have been instructed to transfer stock of this medication to their inpatient departments and are, therefore, unable to fulfill outpatient requests. As of this update, hydroxychloroquine and chloroquine are available through OptumRx Home Delivery. If you are prescribing one of these drugs, colleague members should be directed to obtain the prescription through OptumRx Home Delivery. Additionally, in order to preserve continued supply for chronic indications and ensure access to acute use for malaria, abebiaisis, and COVID-19, the following quantity limits are in place:

- Hydroxychloroquine will be limited to 30 tablets within a 90-day time period with an automatic bypass for members who have utilized at least a 60-day supply within the past 120 days.
- Chloroquine will be limited to 30 tablets within a 90-day time period.
- Members newly starting on hydroxychloroquine for rheumatoid arthritis or systemic lupus will be able to request quantities beyond 30 tablets through a prior authorization process.
- OptumRx will message pharmacists at the point of dispensing to encourage filling for appropriate COVID-19 use.

Trinity Health and OptumRx will continue to review and determine whether there is an ongoing need for quantity limit to remain in place.

As far as alternatives for hydroxychloroquine that will vary based on the diagnosis. If members are unable to fill prescriptions for hydroxychloroquine, they can contact their provider to understand if one of these formulary alternatives may be a viable option during this shortage.

- For treatment of Rheumatoid Arthritis - methotrexate, sulfasalazine, and leflunomide
- For treatment of Lupus - corticosteroids (i.e. prednisone), methotrexate, azathioprine
- For treatment of Malaria - Arakoda, mefloquine, primaquine, quinine sulfate, quinidine sulfate, Krintafel, atovaquone/proguanil hydrochloride, Coartem

Metered-Dose Inhalers

There have been recent updates to our formulary regarding metered-dosed inhalers due to recently released generics. Please see the highlighted below for updates effective immediately as well as how these will change with the January 1, 2021 formulary update. Note: This change was originally scheduled for a July 1, 2020 effective date. However, due to the pandemic, all July 1, 2020 formulary changes were moved to January 1, 2021.

Product Name	MFG	Current Formulary Tier	July 1, 2020 Formulary Tier
PROVENTIL HFA	Merck	Excluded	Excluded
ALBUTEROL HFA	Teva	Generic	Generic
ALBUTEROL HFA	Perrigo	Generic	Generic
PROAIR HFA	Teva	Preferred Brand	Excluded
VENTOLIN HFA	GSK	Preferred Brand	Preferred Brand
ALBUTEROL HFA	PAR	Non-Preferred	Non-Preferred
ALBUTEROL HFA	Prasco	Non-Preferred	Non-Preferred

Note: Copays for the Trinity Health medical plans are \$10 generic, \$15 Preferred Brand and \$30 Non-Preferred Brand for Traditional and Essential Plans. Health Savings Plan members have a \$0 cost share for asthma inhalers and medications.